Linked Life Data

16226108

Source:http://linkedlifedata.com/resource/pubmed/id/16226108

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2005-10-17
pubmed:abstractText
Microvessel density (MVD) has been studied in a number of neoplasias, and apparently, there is a relationship between angiogenesis and tumor progression, response to treatment, and outcome. In pituitary adenoma, the association between MVD and vascular endothelial growth factor (VEGF) with tumor behavior has been described, but correlation with other angiogenic factors such as fetal liver kinase 1 (Flk-1) or proliferative markers is unknown. We investigated MVD, VEGF, and its receptor Flk-1 expression in 60 human pituitary adenomas: 13 growth hormone cell adenomas, 7 prolactin cell adenomas, 5 corticotroph cell adenomas, 2 thyrotroph cell adenomas, and 33 nonfunctioning adenomas (30 gonadotroph cell adenomas and 3 null cell adenomas). We performed immunohistochemistry for CD34, Ki-67, VEGF, and Flk-1. To evaluate MVD, we used 2 methods: the number of vessels per square millimeter and the Chalkley method. Immunohistochemistry results were correlated, as well as with clinicopathologic factors. Adenomas with higher MVD were thyrotroph cell adenomas (299.9 +/- 87.5), and those with lower MVD were prolactin cell adenomas (168.6 +/- 63.3; P = .45, analysis of variance). We found a trend toward higher MVD in the adenomas of older patients (P = .142), but no difference was found regarding sex, extrasellar extension, or Ki-67 (P > .05). However, extrasellar extension was nearly significant when the Chalkley method score was high (P = .056). Low expression of VEGF was seen predominantly in prolactin cell adenomas, and high in nonfunctioning adenomas, or in cases of older patients (P < or = .032). Flk-1 score correlated with VEGF (P = .006). High expression was observed in nonfunctioning adenomas, cases presenting at older ages, and with extrasellar extension (P < or = .022). Our study shows that VEGF and Flk-1 are widely expressed in pituitary adenomas, predominantly in nonfunctioning adenomas and those presenting at older ages. Moreover, Flk-1 is associated with a more aggressive phenotype, and it may have potential therapeutic interest.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0046-8177
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1090-5
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:16226108-Adenoma, pubmed-meshheading:16226108-Adolescent, pubmed-meshheading:16226108-Adult, pubmed-meshheading:16226108-Aged, pubmed-meshheading:16226108-Aged, 80 and over, pubmed-meshheading:16226108-Antibodies, Monoclonal, pubmed-meshheading:16226108-Antigens, CD34, pubmed-meshheading:16226108-Blood Vessels, pubmed-meshheading:16226108-Female, pubmed-meshheading:16226108-Humans, pubmed-meshheading:16226108-Immunohistochemistry, pubmed-meshheading:16226108-Ki-67 Antigen, pubmed-meshheading:16226108-Male, pubmed-meshheading:16226108-Microcirculation, pubmed-meshheading:16226108-Middle Aged, pubmed-meshheading:16226108-Neovascularization, Pathologic, pubmed-meshheading:16226108-Pituitary Neoplasms, pubmed-meshheading:16226108-Vascular Endothelial Growth Factor A, pubmed-meshheading:16226108-Vascular Endothelial Growth Factor Receptor-2
pubmed:year
2005
pubmed:articleTitle
Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
pubmed:affiliation
Department of Pathology, General Universitary Hospital of Alicante, Pintor Baeza s/n, 03010-Alicante, Spain.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't